After Inotuzumab: New Platforms Promise More Than Better Antibody-Drug Conjugates
Executive Summary
Versatile next-generation antibody-drug conjugate platforms promise to turn out ADCs with better specificity and safety than current technologies, as well as combination therapeutics like bi-specific antibodies, but old-school molecules continue to move through clinical trials and gain approval.
You may also be interested in...
Keeping Track: Four Novel Agents Clear FDA; Two Complete Response Letters Issued
The latest drug development news and highlights from our FDA Performance Tracker.
Back To Her Biotech Roots: An Interview With Anna Protopapas
After almost two decades at Millennium/Takeda, Anna Protopapas moves to tiny Mersana Therapeutics, which aims to power up oncology with its Fleximer drug conjugate platform.
Deals Of The Week: Value Surprise!
Sometimes the value of an asset is buried under serial acquisitions and doesn’t come to light for decades.. Also deal news from Janssen/GSK, Takeda/Immunomedics, Quintiles/Muscular Dystrophy Association, Vivus/Auxilium, Lilly/HMP, and Novartis/Immunogen